Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1975 1
1979 2
1981 1
1982 1
1983 2
1985 2
1986 5
1987 8
1988 11
1989 14
1990 11
1991 21
1992 16
1993 15
1994 19
1995 16
1996 12
1997 18
1998 16
1999 26
2000 33
2001 37
2002 39
2003 47
2004 83
2005 82
2006 94
2007 141
2008 167
2009 206
2010 206
2011 222
2012 194
2013 278
2014 356
2015 401
2016 397
2017 463
2018 505
2019 586
2020 655
2021 701
2022 745
2023 732
2024 783
2025 149

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,607 results

Results by year

Filters applied: . Clear all
Page 1
Lysine catabolism reprograms tumour immunity through histone crotonylation.
Yuan H, Wu X, Wu Q, Chatoff A, Megill E, Gao J, Huang T, Duan T, Yang K, Jin C, Yuan F, Wang S, Zhao L, Zinn PO, Abdullah KG, Zhao Y, Snyder NW, Rich JN. Yuan H, et al. Among authors: jin c. Nature. 2023 May;617(7962):818-826. doi: 10.1038/s41586-023-06061-0. Epub 2023 May 17. Nature. 2023. PMID: 37198486 Free PMC article.
LilrB3 is a putative cell surface receptor of APOE4.
Zhou J, Wang Y, Huang G, Yang M, Zhu Y, Jin C, Jing D, Ji K, Shi Y. Zhou J, et al. Among authors: jin c. Cell Res. 2023 Feb;33(2):116-130. doi: 10.1038/s41422-022-00759-y. Epub 2023 Jan 2. Cell Res. 2023. PMID: 36588123 Free PMC article.
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Hao Y, Chen J, Zhang G, Qu S, Li Y, Feng W, Yang M, Liu B, Ouyang W, Liang J, Yu Z, Kang X, Xue S, Yang G, Yan W, Yang Y, Liu Z, Peng Y, Fanslow B, Huang X, Zhang L, Zhao H. Zhao Y, et al. Among authors: jin c. J Hematol Oncol. 2023 May 8;16(1):50. doi: 10.1186/s13045-023-01445-1. J Hematol Oncol. 2023. PMID: 37158938 Free PMC article. Clinical Trial.
7,607 results